tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2018-8-1-12-17tumors-491Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISМультидисциплинарный подход в лечении рецидивных гастроинтестинальных стромальных опухолей: обзор литературы и клиническое наблюдениеMultidisciplinary approach in treatment of recurrent gastrointestinal stromal tumors: a case report and literature reviewОрловаР. В.OrlovaR. V.

Медицинский факультет

онколог, д. м. н., профессор, заведующая, кафедра онкологии

oncologist, MD, DSc Med, Professor, Head of the Department of Oncology

orlova_rashida@mail.ruКащенкоВ. А.KashchenkoV. A.

Медицинский факультет

хирург-онколог, д. м. н., профессор, главный хирург

oncologist, MD, DSc Med, Professor, Chief Surgeon

surg122@yandex.ruХаневичМ. Д.KhanevichM. D.

хирург-онколог, д. м. н., профессор, заместитель главного врача по хирургии

oncologist, MD, DSc Med, Professor, Deputy Chief Surgery Doctor

ХазовА. В.KhazovA. V.

хирург-онколог, заведующий отделением

oncologist, Head of department

ГлузманМ. И.GluzmanM. I.

Медицинский факультет

хирург-онколог, аспирант, кафедра факультетской хирургии

oncology surgeon, post-graduate student of the Department of Faculty Surgery, Medical Faculty

lok2008@list.ruЗиньковскаяА. Е.ZinkovskayaA. E.

хирург-онколог

oncology surgeon

ФГОУ ВПО «Санкт-Петербургский государственный университет»; СПбГУЗ «Городской клинический онкологический диспансер»РоссияSaint Petersburg State University; Saint Petersburg City Oncology ClinicRussian FederationФГОУ ВПО «Санкт-Петербургский государственный университет»; ФГБУЗ «Клиническая больница № 122 им. Л. Г. Соколова ФМБА России»РоссияSaint Petersburg State University; L. G. Sokolov Memorial Hospital № 122Russian FederationСПбГУЗ «Городской клинический онкологический диспансер»РоссияSaint Petersburg City Oncology ClinicRussian FederationФГОУ ВПО «Санкт-Петербургский государственный университет»РоссияSaint Petersburg State UniversityRussian Federation201810052018811217Copyright © Орлова Р.В., Кащенко В.А., Ханевич М.Д., Хазов А.В., Глузман М.И., Зиньковская А.Е., 20182018Орлова Р.В., Кащенко В.А., Ханевич М.Д., Хазов А.В., Глузман М.И., Зиньковская А.Е.Orlova R.V., Kashchenko V.A., Khanevich M.D., Khazov A.V., Gluzman M.I., Zinkovskaya A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/491

В настоящее время стандартом лечения как местных рецидивов, так и отдаленных метастазов гастроинтестинальных стромальных опухолей (ГИСО) является таргетная терапия ингибиторами тирозинкиназ. В качестве первой линии терапии больным назначается иматиниб. Однако в связи с высоким мутационным потенциалом опухолевых клеток у подавляющего числа пациентов в течение времени развивается лекарственная резистентность, что приводит к необходимости назначать терапию второй (сунитиниб) и третьей (регорафениб) линий. Наряду с этим в последнее время актуализируется роль хирургического метода в лечении распространенных форм ГИСО. В данной статье приведен пример длительного наблюдения и лечения пациента с рецидивной ГИСО тонкой кишки. Продемонстрирована эффективность комплексного подхода в лечении этой сложной категории больных.

Currently, the standard treatment of recurrent gastrointestinal stromal tumors (GIST) is life-long targeted therapy with tyrosine kinase inhibitors. Imatinib is administered as a first-line therapy. Due to the high mutational potential of tumor cells the secondary drug resistance develops in an overwhelming number of patients, which leads to the necessity of switching to second (sunitinib) and third (regorafenib) line therapy. In addition, the role of the surgical method in the complex treatment of advanced GIST has recently been updated. This article gives an example of long-term follow-up and treatment of a patient with recurrent small bowel GIST. The effectiveness of the combined approach in the treatment of this complex category of patients has been demonstrated.

рецидивная гастроинтестинальная стромальная опухольтаргетная терапияиматинибсунитинибрегора- фенибциторедуктивная хирургияrecurrent gastrointestinal stromal tumor (GIST)targeted therapyimatinibsunitinibregorafenibcytoreductive surgeryReferencesIorio N., Sawaya R.A., Friedenberg F.K. Review article: the biology, diagnosis and management of gastrointestinal stromal tumours. Aliment. Pharmacol. Ther. 2014. Vol. 39. No. 12. pp. 1376–1386.Iorio N., Sawaya R.A., Friedenberg F.K. Review article: the biology, diagnosis and management of gastrointestinal stromal tumours. Aliment. Pharmacol. Ther. 2014. Vol. 39. No. 12. pp. 1376–1386.Miettinen M., Lasota J. Gastrointestinal stromal tumors. Gastroenterol. Clin. North. Am. 2013. Vol. 42. No. 2. pp. 399–415.Miettinen M., Lasota J. Gastrointestinal stromal tumors. Gastroenterol. Clin. North. Am. 2013. Vol. 42. No. 2. pp. 399–415.Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat.Rev. Clin. Oncol. 2012. Vol. 9. pp. 351–358.Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat.Rev. Clin. Oncol. 2012. Vol. 9. pp. 351–358.Vadakara J., von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol. Oncol. Clin. North. Am. 2013. Vol. 27. No. 5. pp. 905–920.Vadakara J., von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol. Oncol. Clin. North. Am. 2013. Vol. 27. No. 5. pp. 905–920.Hirota S., Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol. Int. 2006. Vol. 56. No. 1. pp. 1–9.Hirota S., Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol. Int. 2006. Vol. 56. No. 1. pp. 1–9.Serrano C., George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther.Adv. Med. Oncol. 2014. Vol. 6. No. 3. p. 115–127.Serrano C., George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther.Adv. Med. Oncol. 2014. Vol. 6. No. 3. p. 115–127.Shirley M., Keating G.M. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Drugs. 2015. Vol. 75. No. 9. pp. 1009–1017.Shirley M., Keating G.M. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Drugs. 2015. Vol. 75. No. 9. pp. 1009–1017.ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014. Vol. 25. Suppl. 3. pp. 321–326.ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014. Vol. 25. Suppl. 3. pp. 321–326.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guideline): soft tissue sarcoma. Version 1.2017. http://www.nccn.org.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guideline): soft tissue sarcoma. Version 1.2017. http://www.nccn.org.Siddiqui M.A. A., Scott L. J. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs. 2007. Vol. 67. No. 5. pp. 805–820.Siddiqui M.A. A., Scott L. J. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs. 2007. Vol. 67. No. 5. pp. 805–820.Heinrich M., Corless C., Blanke C. et al.: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 2006. Vol. 24. pp. 4764–4774.Heinrich M., Corless C., Blanke C. et al.: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 2006. Vol. 24. pp. 4764–4774.Heinrich M.C., Maki R.G., Corless C. L. et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib resistant gastrointestinal stromal tumor. J. Clin. Oncol. 2008. Vol. 26. pp. 5352–5359Heinrich M.C., Maki R.G., Corless C. L. et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib resistant gastrointestinal stromal tumor. J. Clin. Oncol. 2008. Vol. 26. pp. 5352–5359Liegl B., Kepten I., Le C. et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 2008. Vol. 216. pp. 64–74Liegl B., Kepten I., Le C. et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 2008. Vol. 216. pp. 64–74Wang W. L., Conley A., Reynoso D. et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011. Vol. 67. pp. 15–24.Wang W. L., Conley A., Reynoso D. et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011. Vol. 67. pp. 15–24.Guo T., Hajdu M., Agaram N.P. et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin. Cancer Res. 2009. Vol. 15. No. 22. pp. 6862–6870.Guo T., Hajdu M., Agaram N.P. et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin. Cancer Res. 2009. Vol. 15. No. 22. pp. 6862–6870.Deeks E.D., Keating G.M. Sunitinib. Drugs. 2006. Vol. 66. No. 17. pp. 2255–2266.Deeks E.D., Keating G.M. Sunitinib. Drugs. 2006. Vol. 66. No. 17. pp. 2255–2266.Kang Y.-K., Ryu M.-H., Yoo C. et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013. Vol. 14. pp. 1175-1182.Kang Y.-K., Ryu M.-H., Yoo C. et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013. Vol. 14. pp. 1175-1182.George S., Wang Q., Heinrich M.C. et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J. Clin. Oncol. 2012. Vol. 30. No.George S., Wang Q., Heinrich M.C. et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J. Clin. Oncol. 2012. Vol. 30. No.pp. 2401–2407. 19. US FDA. Stivarga (regorafenib): prescribing information. 2015. http://www.fda.gov.pp. 2401–2407. 19. US FDA. Stivarga (regorafenib): prescribing information. 2015. http://www.fda.gov.European Medicines Agency. Stivarga: summary of product characteristics. 2015. http://www.ema.europa.eu.European Medicines Agency. Stivarga: summary of product characteristics. 2015. http://www.ema.europa.eu.Demetri G.D., Reichardt P., Kang Y.-K. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013. Vol. 381. No. 9863. pp. 295–302.Demetri G.D., Reichardt P., Kang Y.-K. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013. Vol. 381. No. 9863. pp. 295–302.Park S. J., Ryu M.H., Ryoo B.Y. et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann. Surg. Oncol. 2014. Vol. 21. pp. 4211–4217.Park S. J., Ryu M.H., Ryoo B.Y. et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann. Surg. Oncol. 2014. Vol. 21. pp. 4211–4217.Sym S. J., Ryu M.H., Lee J. L. et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J. Surg. Oncol. 2008. Vol. 98. pp. 27–33.Sym S. J., Ryu M.H., Lee J. L. et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J. Surg. Oncol. 2008. Vol. 98. pp. 27–33.Du C.Y., Zhou Y., Song C. et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur. J. Cancer. 2014. Vol. 50. pp. 1772–1778.Du C.Y., Zhou Y., Song C. et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur. J. Cancer. 2014. Vol. 50. pp. 1772–1778.Wardelmann E., Losen I., Hans V. et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int. J. Cancer. 2003. Vol. 106. No. 6. pp. 887–895.Wardelmann E., Losen I., Hans V. et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int. J. Cancer. 2003. Vol. 106. No. 6. pp. 887–895.Wang C.M., Fu H., Zhao G. F. et al. Secondary resistance to imatinib in patients with gastrointestinal stromal tumors through an acquired KIT exon 17 mutation. Mol.Med. Rep. 2009. Vol. 2. No. 3. p. 455–460.Wang C.M., Fu H., Zhao G. F. et al. Secondary resistance to imatinib in patients with gastrointestinal stromal tumors through an acquired KIT exon 17 mutation. Mol.Med. Rep. 2009. Vol. 2. No. 3. p. 455–460.Spitaleri G., Biffi R., Barberis M. et al. Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). OncoTargets Ther. 2015. Vol. 8. pp. 1997–2003.Spitaleri G., Biffi R., Barberis M. et al. Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). OncoTargets Ther. 2015. Vol. 8. pp. 1997–2003.

The authors declare that there are no conflicts of interest present.